Profusa Signs $30 Million Letter of Intent to Acquire PanOmics Diagnostics Platform
The pending all-stock move would pair a DNA sequencing platform with Profusa’s biosensors to speed lab test validation for pancreatic cancer.
Overview
- Profusa announced a letter of intent Monday to buy BioInsights’ PanOmics multi-omics diagnostics platform for about $30 million paid in equity.
- The LOI outlines exclusive rights to PanOmics, a 3% royalty to BioInsights, access to clinical samples, and a board nominee, with closing still subject to due diligence and shareholder approval.
- Profusa said the tie-up with its Lumee oxygen sensor and its Mayo Clinic work aims to enable rapid lab-developed tests and improve monitoring during pancreatic surgery.
- Shares jumped more than 170% after the news, according to CoinCentral and Blockonomi, in a sharp move for a micro-cap stock those outlets said is still down about 99% year over year.
- To support the plan, Profusa expanded its convertible notes capacity to as much as $12.2 million and issued a $555,555 tranche to Ascent Partners, canceled a $15 million stock offering, sold its Bitcoin holdings, and raised 2026 revenue guidance to $1.5–$3 million on stronger European orders.